TISIDB

Summary
Symbol	STC2
Name	stanniocalcin 2
Aliases	STC-2; STCRP; STC-related protein; stanniocalcin-related protein; Stanniocalcin-2
Chromosomal Location	5q35.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Secreted
Domain	PF03298 Stanniocalcin family
Function	Has an anti-hypocalcemic action on calcium and phosphate homeostasis.

> Gene Ontology [ TOP ]
Biological Process	GO:0001666 response to hypoxia GO:0001890 placenta development GO:0001893 maternal placenta development GO:0002115 store-operated calcium entry GO:0006816 calcium ion transport GO:0006874 cellular calcium ion homeostasis GO:0006875 cellular metal ion homeostasis GO:0006979 response to oxidative stress GO:0006986 response to unfolded protein GO:0007565 female pregnancy GO:0007566 embryo implantation GO:0007584 response to nutrient GO:0009991 response to extracellular stimulus GO:0010817 regulation of hormone levels GO:0010959 regulation of metal ion transport GO:0030968 endoplasmic reticulum unfolded protein response GO:0031667 response to nutrient levels GO:0032350 regulation of hormone metabolic process GO:0033273 response to vitamin GO:0033280 response to vitamin D GO:0034620 cellular response to unfolded protein GO:0034976 response to endoplasmic reticulum stress GO:0035264 multicellular organism growth GO:0035966 response to topologically incorrect protein GO:0035967 cellular response to topologically incorrect protein GO:0036293 response to decreased oxygen levels GO:0036294 cellular response to decreased oxygen levels GO:0040014 regulation of multicellular organism growth GO:0040015 negative regulation of multicellular organism growth GO:0042445 hormone metabolic process GO:0042446 hormone biosynthetic process GO:0043434 response to peptide hormone GO:0044706 multi-multicellular organism process GO:0045926 negative regulation of growth GO:0046697 decidualization GO:0046885 regulation of hormone biosynthetic process GO:0048608 reproductive structure development GO:0048638 regulation of developmental growth GO:0048640 negative regulation of developmental growth GO:0051924 regulation of calcium ion transport GO:0055074 calcium ion homeostasis GO:0060135 maternal process involved in female pregnancy GO:0061458 reproductive system development GO:0070482 response to oxygen levels GO:0070838 divalent metal ion transport GO:0071453 cellular response to oxygen levels GO:0071456 cellular response to hypoxia GO:0072503 cellular divalent inorganic cation homeostasis GO:0072507 divalent inorganic cation homeostasis GO:0072511 divalent inorganic cation transport GO:1901652 response to peptide GO:2001256 regulation of store-operated calcium entry
Molecular Function	GO:0005179 hormone activity GO:0020037 heme binding GO:0046906 tetrapyrrole binding
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	STC2
Name	stanniocalcin 2
Aliases	STC-2; STCRP; STC-related protein; stanniocalcin-related protein; Stanniocalcin-2
Chromosomal Location	5q35.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between STC2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	STC2
Name	stanniocalcin 2
Aliases	STC-2; STCRP; STC-related protein; stanniocalcin-related protein; Stanniocalcin-2
Chromosomal Location	5q35.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of STC2 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	STC2
Name	stanniocalcin 2
Aliases	STC-2; STCRP; STC-related protein; stanniocalcin-related protein; Stanniocalcin-2
Chromosomal Location	5q35.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of STC2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-1.239	0.00264
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-1.418	0.0889
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-1.107	0.0987
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.402	0.299
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.312	0.804
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.516	0.74
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.358	0.464
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.025	0.979
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.859	0.34
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.336	0.835
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.538	0.501
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.121	0.492

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of STC2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	2.7	1	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	3.4	0.3	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	STC2
Name	stanniocalcin 2
Aliases	STC-2; STCRP; STC-related protein; stanniocalcin-related protein; Stanniocalcin-2
Chromosomal Location	5q35.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of STC2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	STC2
Name	stanniocalcin 2
Aliases	STC-2; STCRP; STC-related protein; stanniocalcin-related protein; Stanniocalcin-2
Chromosomal Location	5q35.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of STC2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by STC2. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	STC2
Name	stanniocalcin 2
Aliases	STC-2; STCRP; STC-related protein; stanniocalcin-related protein; Stanniocalcin-2
Chromosomal Location	5q35.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of STC2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	STC2
Name	stanniocalcin 2
Aliases	STC-2; STCRP; STC-related protein; stanniocalcin-related protein; Stanniocalcin-2
Chromosomal Location	5q35.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of STC2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	STC2
Name	stanniocalcin 2
Aliases	STC-2; STCRP; STC-related protein; stanniocalcin-related protein; Stanniocalcin-2
Chromosomal Location	5q35.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between STC2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	STC2
Name	stanniocalcin 2
Aliases	STC-2; STCRP; STC-related protein; stanniocalcin-related protein; Stanniocalcin-2
Chromosomal Location	5q35.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting STC2 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse STC2